Method for early diagnosis of proliferative diabetic retinopathy

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides an ex vivo diagnostic method and kit for the early detection and risk assessment of proliferative diabetic retinopathy (DRP) in diabetes mellitus (DM) patients. The method involves analyzing specific gene expression levels and matrix metalloproteinase (MMP) enzyme activities in a body fluid (such as blood) to identify molecular markers linked with DRP development and progression. It allows prediction of disease risk, early diagnosis, and monitoring of disease progression using measurable biomarkers such as NF-kappaB, XIAP, TIMP-1, TIMP-2, Ly-GDI, MMP-2, and MMP-9, and their activity ratios (MMP-2:TIMP-2 and MMP-9:TIMP-1).

Use CasesContent extracted from patent full text and abstract with AI.

• Early diagnosis of proliferative diabetic retinopathy in diabetic patients based on blood tests.
• Assessment of individual risk for developing proliferative DRP or for DRP progression in known diabetic individuals.
• Monitoring of disease progression and effectiveness of interventions in DRP patients.
• Large-scale screening programs in clinical laboratories for diabetic populations at risk of retinopathy.
• Research into new therapeutic targets for diabetic retinopathy by studying the identified molecular markers.
• Personalized diabetes management by risk stratification and preventive measures based on molecular profiling.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables early and non-invasive diagnosis of proliferative diabetic retinopathy, potentially before clinical symptoms arise.
• Allows for personalized risk assessment and disease monitoring with quantifiable molecular markers.
• Facilitates timely, targeted interventions to prevent vision loss in diabetic patients.
• Provides an objective and reproducible method compared to traditional imaging techniques, which only show existing disease status.
• Supports prevention of further secondary diabetic complications by identifying high-risk individuals.
• Offers a standardized kit that can be implemented in routine clinical labs, making advanced molecular diagnostics widely accessible.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides an ex vivo method for diagnosis, especially early diagnosis, of proliferative diabetic retinopathy. Furthermore, it provides a kit for performing said method.